# US 2002/0058651 A1 · Estra-1,3,5(10), 16-tetraene derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058651 A1
- Document ID: US20020058651A1
- Status: Published application
- Kind: A1
- Application number: 09/859,599
- Filed: 2001-05-18
- Published: 2002-05-16
- Earliest claimed: 1999-04-13
- Assignees: Kyowa Hakko Kogyo Co., Ltd.; Duquesne University of the Holy Ghost
- Inventors: Yoji Ino; Nobuyoshi Amishiro; Taisuke Nakata; Hiroyuki Ishida; Shiro Akinaga; Chikara Murakata; Pui-Kai Li
- Web page: https://patentgrep.com/patent/US20020058651A1

## CPC

- C07J 3/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Estra-1,3,5(10),16-tetraene derivatives represented by the following formula (I): 1 (wherein R1 represents hydroxy, alkoxy, or NR2R (wherein R2 and R3 are the same or different, and each represents hydrogen, straight-chain lower alkyl having 1 to 3 carbon atoms, or branched-chain lower alkyl having 3 to 8 carbon atoms)), or pharmaceutically acceptable salts thereof.

## Claims

### Claim 1

An estra-1,3,5(10),16-tetraene derivative represented by the following formula (I):
15
(wherein R1 represents hydroxy, alkoxy, or NR2R3 (wherein R2 and R3 are the same or different, and each represents hydrogen, straight-chain lower alkyl having 1 to 3 carbon atoms, or branched-chain lower alkyl having 3 to 8 carbon atoms)), or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The estra-1,3,5(10),16-tetraene derivative according to claim 1, wherein R1 is hydroxy or NR2R3 (wherein R2 and R3 have the same meanings as defined above), or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The estra-1,3,5(10),16-tetraene derivative according to claim 1, wherein R1 is hydroxy, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

An agent for the treatment or prevention of a disease concerned by steroid sulfatase, which comprises at least one of the estra-1,3,5(10),16-tetraene derivatives according to claim 1 or pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 1)

A method for treating or preventing a disease concerned by steroid sulfatase, which comprises administering at least one of the estra-1,3,5(10),16-tetraene derivatives according to claim 1 or pharmaceutically acceptable salts thereof.
